NCT04187404View on ClinicalTrials.gov

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

May 30, 2024

Study Completion Date

October 2, 2024

Conditions
Adrenocortical CarcinomaPheochromocytomaParaganglioma
Interventions
BIOLOGICAL

EO2401

Multiple dose of EO2401

BIOLOGICAL

Nivolumab

Multiple dose of nivolumab

Trial Locations (12)

1081

Amsterdam UMC, location VUmc, Amsterdam

2100

Rigshospitalet, Copenhagen

13915

Assistance Publique - Hôpitaux de Marseille - Hôpital Nord, Marseille

17176

Karolinska University Hospital, Stockholm

25121

Azienda Ospedaliera Spedali Civili, Brescia

59037

Chu Lille, Lille

69008

Centre Léon Bérard, Lyon

77030

MD Anderson Cancer Center, Houston

94800

Institut Gustave Roussy, Villejuif

97080

Universitätsklinikum Würzburg, Würzburg

Unknown

Lmu Klinikum, München

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Lead Sponsor

Enterome
All Listed Sponsors
lead

Enterome

INDUSTRY

NCT04187404 - A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | Biotech Hunter | Biotech Hunter